Expert consensus on rational use of anti-osteoporosis agents(2023)
Osteoporosis has been the most prevalent bone disease.It is characterized clinically by systemic low bone mass and microstructural damage to bone tissue,resulting in heightened vulnerability to fractures due to greater bone fragility.With a rapid aging of society,the prevalence of osteoporosis has markedly spiked.However,its public awareness,diagnostic rate and treat-ment level remain low.Osteoporotic fractures carry severe consequences,particularly among elders,leading to disability and even death.Consequently,osteoporosis and associated fractures have emerged as critical public health issues in China.Anti-osteoporosis agents may be divided into anti-resorptives,anabolics of stimulating bone formation and dual-acting drugs.Based upon the latest clinical trials and drug application status for osteoporosis,a multidisciplinary panel of experts assembled by Hospital Pharmacy Committee of Chinese Pharmaceutical Association has collaborated to develop this consensus for standardizing rational drug dosing for improved patient outcomes and satisfactions.
NETL
